Copyright © 2021. Inderes Oyj. All rights reserved.

Pihlajalinna

Latest reports

Analyst

Olli Vilppo

Olli Vilppo

Analyytikko

Read more

Latest insider trading

Net impact profile

Third party research
16.8.
2021

Pihlajalinna’s Q2 served a small positive surprise relative to estimates. We are confident operating margin and multiple expansion potential enable solid long-term upside.

Third party research
13.8.
2021

Pihlajalinna’s revenue and profitability continued to improve and were slightly above estimates. The company reiterates its existing guidance.Rating; Buy with target price 13,2 EUR.

Third party research
10.8.
2021

Pihlajalinna reports Q2 results on Fri, Aug 13.

Third party research
10.6.
2021

We see Pihlajalinna as a margin turnaround case in the near term, with good growth potential longer term in the consolidated and structurally growing Finnish healthcare services market.

Third party research
10.5.
2021

Pihlajalinna’s Q1 result outpaced the expectations. Revenue increased by ~5% and adj. EBIT by ~59% y/y. We have slightly increased our 21E estimates and keep our rating “BUY” with TP of EUR 13.2 (13.0).

Third party research
10.5.
2021

Pihlajalinna had a strong Q1. We see potential for clearly higher profitability in 2021-23E compared to pre-pandemic levels and see a possible attractive margin turnaround case ahead at low valuations.

Third party research
7.5.
2021

Pihlajalinna had a strong Q1. We see potential for clearly higher profitability in 2021-23E compared to pre-pandemic levels and see a possible attractive margin turnaround case ahead at low valuations.

Third party research
7.5.
2021

Pihlajalinna’s Q1 figures beat our estimates. Q1 revenue amounted EUR 140m (+5.2%) vs. EUR 137m/140m Evli/cons, while adj. EBIT landed at EUR 6.7m vs. EUR 5.6m/6.1m Evli/cons estimates.

Third party research
30.4.
2021

Pihlajalinna reports its Q1 report on next week’s Friday, 7th of May. Despite the worsened COVID-19 situation during Q1, we expect fairly good quarterly figures.

Third party research
31.3.
2021

Pihlajalinna held its CMD yesterday, 30th of March. The focus of the event was on the company’s strategic priorities and the future of the social and healthcare market. Financial targets remained unchanged. Thus, there were no changes in the big picture. We keep our rating “BUY” with TP of EUR 13.0 (12.0).

Pihlajalinna